Fiskus, Warren <br/><br/>
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.  [electronic resource] 

 -  Blood cancer journal  01 2019 
 - 4 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2044-5385 
<br/><br/><label>Standard No.: </label>10.1038/s41408-018-0165-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Binding Sites<br/>Biomarkers, Tumor<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Drug Synergism<br/>Female<br/>Humans<br/>Indoles--pharmacology<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Myeloid Cell Leukemia Sequence 1 Protein--antagonists & inhibitors<br/>Neoplastic Stem Cells--drug effects<br/>Protein Binding<br/>Protein Kinase Inhibitors--pharmacology<br/>Proteins--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>Pyridones--pharmacology<br/>Sulfonamides--pharmacology<br/>Xenograft Model Antitumor Assays